Date: 2015-09-02
Type of information: Nomination
Compound:
Company: AmpliPhi BioSciences (USA - VA)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 2, 2015, AmpliPhi Biosciences announced that Alexander Gaidamaka has been appointed as the new Vice President of Chemistry, Manufacturing and Control. Dr. Gaidamaka brings extensive experience to the Company, with over 25 years in the life sciences sector. Prior to his role at AmpliPhi, Alexander served as CEO and CSO of Personalized OncoTherapeutics Inc. He has held executive R&D, product development and quality control roles at Pharma Green LLD, Merial, Sanofi Pasteur, Bioniche Life Sciences Inc. and Biopharm JSC. Dr. Gaidamaka was also previously head of the Department of Immunopharmacology & Allergology at the All-Union Research Institute of Drug Chemistry and Technology, Ukraine. He received a Ph.D. in immunology and microbiology and D.V.M from the Kharkov State Veterinary Academy, Ukraine. In June, AmpliPhi announced that its dedicated bacteriophage manufacturing facility in Ljubljana, was cleared by JAZMP, the Agency of the Republic of Slovenia for Medicinal Products and Medical Devices, to manufacture bacteriophages under current Good Manufacturing Practices (cGMP) standards. AmpliPhi will produce Staphylococcus aureus and Pseudomonas aeruginosa bacteriophages to be used in planned human clinical trials. AmpliPhi is currently advancing three pre-clinical programs as therapies to treat methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa infections in cystic fibrosis and Clostridium difficile.
Financial terms:
Latest news:
